New Delhi, Jun 19 (PTI) Sun Pharmaceutical Industries Ltd on Wednesday said it has received a warning letter from the US health regulator for its Dadra facility over violation of manufacturing norms.

The warning letter by the US Food and Drug Administration (USFDA) summarises violations with respect to Current Good Manufacturing Practice (cGMP) regulations, Sun Pharma said in a regulatory filing.

Also Read | Railway Recruitment 2024: RRB Releases Notification for 7,911 Posts, Know Eligibility Criteria and How to Apply.

The contents of the warning letter shall be made public by the USFDA in due course, it added.

This intimation is further to our communication dated April 11, 2024, about Dadra facility receiving OAI status by the USFDA.

Also Read | PM Kisan Samman Nidhi Yojana: PM Narendra Modi Releases Rs 20,000 Crore, Know Steps to Check Beneficiary Status and Reasons for Rejection.

On April 11, Sun Pharma had informed stock exchanges that its Dadra facility had received Official Action Indicated (OAI) status from the USFDA.

It followed an inspection at the company's Dadra facility from December 4 to December 15, 2023.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)